The future of cannabis use is in edibles. I could be wrong, but that’s my prediction. Smoking and vaping won’t disappear, but as we learn more about cannabis, I believe people will be less inclined to smoke if quality alternatives are given. And it’s happening already. What could this trend mean as medicinal use expands?
The Health & Wellness and Cannabis industries are beginning to merge in some exciting ways. Some companies are taking bold first steps, delivering Cannabis infused products claiming to be nootropics.
For those unfamiliar, nootropics are natural substances that can increase cognitive functionality: also brain enhancers. Though the word is not commonly used yet, things like green tea, kava and even blue spectrum light are proven nootropics.
Two companies are at the vanguard of creating this environment.
Koios who is preparing to launch a line of nootropic beverages, and
Humanity Medicinals who is preparing a line of nootropic capsules.
Koios is taking the step of mixing CBD with a nootropic stack to “enhance focus, concentration, mental capacity, memory retention, cognitive function, alertness, brain capacity and create all day mental clarity.” They are taking their proprietary stack and adding CBD to it.
Humanity Medicinals (HM) is making “cannabis products for real life.” What’s unique about their approach is that HM blends micro-dosed THC with various nootropic stacks. They intend on combining the effects of whole plant profiles with nootropic stacks for specific enhancements (sleep, focus, etc.).
Clinical Backing Before Clinical Research
As readers of my previous post might consider, I am wary of pre-clinical claims for the potential of losing public trust. Nootropics appropriately used with cannabis can underline the inherent benefits. I am very excited at what this can bring. The addition of clinically proven nootropic ingredients in formulations makes the “medicinal” claim more than a guess or hope.
It’s been nearly a half-century since modern science has begun publishing the results of nootropics with study of piracetam. From Ginkgo Biloba extract being an effective treatment in Alzheimer’s, to coffee increasing alertness, well-being and concentration; cognitive enhancers have become an everyday part of our lives.
That’s like giving an “Undersell… but over deliver” approach to product development. Here, the risks of overstating become minimized and when the clinical studies start rolling out concerning cannabis benefits, then people will feel like they are getting added value. I can get down with that.
As cannabis use expands. We will refine the delivery methods. That refinement logically ends in edible delivery for regular cannabis users, especially medical users.
There will be considerations and research to be done in product development; such as will some forms of THC negatively interact with nootropic stacks?Or What doses of formulations consistently produce desire effects among all people?
In my humble opinion, that these steps are being taken is a major first step to unlocking the potential of cannabis to be what advocates want. I salute companies willing to take the risk on proving claims of the medical applications in a clear way.
Feel free to comment.
Wolfgang Froestl , Andreas Muhs , Andrea Pfeifer,” Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors.”Journal of Alzheimer’s Disease, Issue: 4, Volume: 32, Pages: 793-887. | Nov 14, 2012
F. V. DeFeudis and K. Drieu, “ Ginkgo Biloba Extract (EGb 761) and CNS Functions Basic Studies and Clinical Applications”, Current Drug Targets (2000) 1: 25. https://doi.org/10.2174/1389450003349380
Nehlig A. “Effects of coffee/caffeine on brain health and disease: What should I tell my patients?” Practical Neurology 2016;16:89-95.
Caveat: Medical users will likely use properly dosed edibles unless clinical studies show some other form of delivery produces desired outcomes in specific cases where inhalation is more appropriate due to the faster onset.